We are excited to announce that BTG is now officially part of Boston Scientific. By merging our leading interventional oncology, venous and arterial portfolios, as well as our continuing investment in clinical science and medical education, we are positioned to be a complete clinical partner for our physicians. More importantly, as one organization, we can advance vascular and cancer solutions for more patients around the world. 
BSC and BTG stats
doctor quote

“…with Boston Scientific, you [now] have all the best products under one umbrella. It really offers an advantage to the company as well [as] larger healthcare systems…” 

Dr. Ed Kim
Director of Interventional Oncology
Mount Sinai Medical Center, NYC 


Interventional Oncology

Boston Scientific can now provide interventional radiologists with tools for access and delivery, therapeutic technologies designed to extend and improve life, and clinical evidence to improve patient access to these therapies. 
Interventional Oncology products
Venous products
Venous portfolio


Boston Scientific can now expand the treatment of venous disease, including technology and clinical leadership in the interventional treatment of deep vein thrombosis, pulmonary embolism and deep venous obstruction.


Boston Scientific’s best-in-class arterial portfolio offers differentiated drug-eluting technologies backed by unparalleled clinical evidence, along with a full set of core products to help interventionalists treat the toughest PAD and CLI cases. 
Customer Support and Service

Customer Support and Service

Our goal is to continue to provide you with the highest level of customer support and service. For now, there will be no changes to the ordering process, so please continue working with your current Boston Scientific and/or BTG sales representative to order products. We will notify you of changes as appropriate.

Read the press release.

Press Release

View the global announcement about Boston Scientific and BTG joining forces. 

Sign up to receive updates

Stay Up-to-Date 

Receive emails on the latest advances, news and innovations.